|Bid||32.09 x 700|
|Ask||32.14 x 100|
|Day's range||32.10 - 32.29|
|52-week range||29.83 - 37.39|
|PE ratio (TTM)||27.40|
|Earnings date||31 Jul 2017 - 4 Aug 2017|
|Dividend & yield||1.28 (3.98%)|
|1y target est||37.53|
Total prescriptions of Pfizer's eczema drug Eucrisa have flattened out over recent weeks as Regeneron and Sanofi's Dupixent has picked up steam.
The quest has seemed so elusive that it regularly draws comparison to the Holy Grail and unicorns.
Why Pfizer, Novartis, and Sanofi rank at the top of all dividend stocks in the generic-drug industry.